Try it
PSM · Clinical trials: intention-to-treat analysis
Sample itemIn a trial, 200 patients are randomised equally to surgery or medical therapy. In the surgical arm, 30 patients refuse the operation and receive medical therapy instead. To preserve the benefits of randomisation, how should the outcomes be analysed?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
D. All 200 patients analysed in the arm to which they were originally randomised
Intention-to-treat analysis keeps every participant in the group to which they were randomised, regardless of what treatment they actually received. This preserves comparable prognostic balance between groups and reflects real-world effectiveness, including non-compliance. Excluding or re-allocating patients (per-protocol or as-treated analysis) reintroduces selection bias.
Option by option
A. Only patients who completed their assigned treatment analysed
A per-protocol analysis includes only completers, who differ systematically from non-completers.
B. The 30 non-compliant patients excluded from the analysis
Excluding the non-compliant patients breaks the comparability of the groups and can bias the result.
C. The 30 patients analysed in the medical therapy arm they actually received
As-treated analysis moves patients on the basis of a post-randomisation behaviour, which is not random.
D. All 200 patients analysed in the arm to which they were originally randomised (correct)
Analysing everyone as randomised maintains the balance created by randomisation.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More PSM questions
- BiostatisticsOf 200 people who truly have a disease, a screening test is positive in 180. What is the…
- Environmental healthAfter one hour of contact time, what residual free chlorine level is generally recommend…
- EpidemiologyWhich study design is the most efficient for investigating risk factors of a rare disease?
- BiostatisticsIn hypothesis testing, a Type I error is: